CHARACTERIZATION OF CAR
Characterization of CAR involves evaluating its expression, binding specificity, and functional activity on engineered T or NK cells. Techniques like flow cytometry assess surface CAR expression, while cytotoxicity assays measure tumor-killing efficacy.
Binding affinity to the target antigen is confirmed through in vitro binding studies. Functional validation ensures proper CAR signaling and cytokine release upon antigen engagement.
Allianz Bio, in partnership with ACRO Biosystems, offers a comprehensive CAR characterization product line. This includes CAR protein targets, MHC molecules for antigen presentation studies, and high-quality Anti-CD19 CAR antibodies.
Additionally, the portfolio features CAR linker antibodies and bispecific antibodies to support functional and structural CAR evaluation.
CAR Characterization Product Line
- Car protein target
- MHC molecules
- Anti-CD19 CAR
- Car linker antibody
- Bispecific antibody
Key Feature
- Expression Analysis -Detect CAR expression on T/NK cells via flow cytometry.
- Target Binding Validation -Confirm antigen binding using CAR targets and MHC molecules.
- Functional Testing -Assess CAR activity through cytokine release and cytotoxicity assays.
- Structure Evaluation -Analyze CAR configuration with linker-specific antibodies.
- Bispecific Antibody Support -Enable dual-target studies and immune redirection.
